中国企业出海，为什么欧盟该是你的首选？
2015 年前后，中国药械企业一谈出海，眼睛全盯着 FDA。今天，如果让我给董事会一句话建议，我会说：第一站，先选欧盟，而不是美国。
理由可以浓缩成一句——FDA 是产品准入，欧盟才是企业准入。下面把这套逻辑拆开讲。
一、出海已经不是选择题，是必选题
当内需萎缩、医保压价成为长期结构性现实，走向全球才是良策。日本药械企业 90 年代的答卷摆在那里：
- 武田（Takeda） 从"日本最大"走到"全球化生存"，靠的是早早把增长曲线画到海外；
- 第一三共（Daiichi Sankyo） 被市场"逼"成了 ADC 王者；
- 大冢（Otsuka） 不走主流，但全球化做得极彻底。
中国企业也早就动起来了：百济神州把替雷利珠单抗（PD-1）授权给 Amgen，和黄医药把 Savolitinib 交给阿斯利康，荣昌生物把 ADC 平台早期授权给 Seagen——这是"联姻出海"；麦科田 2022 年并购英国 Penlon，健康元 2025 年斥资 15.87 亿元收购越南 IMP 制药——这是"借壳出海"；迈瑞、联影、微创、复星自建队伍或找当地代理——这是"借力出海"。
路径不同，但方向一致：出去，是迟早的事。
二、一张表看清：为什么是欧盟
把全球几个主要市场放一起比，结论很直观（数据为行业估算与公开观察，2025 年）：
| 指标 | 美国 | 欧盟 | 中国 | 东南亚 |
|---|---|---|---|---|
| 市场规模 | 最大（约 40–50%） | 较大（约 20%） | 大（约 7.5%） | 中等（约 5%），增长快 |
| 支付能力 & 定价 | 最高 | 高 | 中 | 中偏下 |
| 审批难度 | 最高 | 中高 | 中高 | 低中 |
| 监管稳定性 | 高（但政策波动） | 稳定、趋严格 | 中（受医保降价影响大） | 低中（各国不统一） |
| 全球认可度 | 高 | 高 | 中 | 低 |
全球药械市场预计在 1.7–2.1 万亿美元规模（2025 估计）。美国确实最大，但"最大"不等于"最好进"。
三、美国的"隐性门槛"，比纸面更难
很多人只看到 FDA 审评严格，没看到它背后叠加的东西。在器械领域，欧盟整体偏向 技术合规 + 医疗价值，政治因素相对弱；而美国监管常常不是纯技术问题，医疗器械出海在美国往往还要过这几关：
- 数据安全 / 网络安全审查
- 国家安全审查（CFIUS）
- 政治与舆论风险
- 对"中国制造"的额外审视
再加上：欧盟是分散审批，美国是单一强监管中心。 CE 由各家 Notified Body（公告机构）审核，各国执行有弹性、有博弈空间，中小创新和成熟器械更容易"分批突破"；FDA 是唯一裁判，标准极度统一、严格、可追溯，一次失败，全球声誉都可能受影响。
临床数据上也是：欧盟"够用即可"——接受中国本土临床数据、回顾性研究、与同类产品的等效性证明；FDA 更强调前瞻性、多中心、随机对照，GCP 体系极严，数据可审计性极强。对多数中国企业，欧盟的门槛更现实。
四、正确的出海路径：中国 → 欧盟 → 拉美/中东 → 再回美国
对多数中国药械企业，我的建议路径是：
中国 → 欧盟 → 拉美/中东 → 再回美国。
欧盟的价值在于帮你"打底"：打磨 QMS（质量体系）、建立全球合规经验、积累真实世界使用数据、拿到"国际背书"（CE 标志）。EMA 的批准，意味着你的产品在科学上被全球最严格体系之一认可。等这些都成熟了，再去叩 FDA，成功率才显著提升。
更关键的是：CE 不只是欧盟的门票，它是全球通行证。 WHO PQ、UNICEF、Global Fund 都认可 CE——这些国际组织要的就是一套被证明可靠、可审计、可持续的质量背书体系，而 CE 恰好满足：基于 ISO 国际共识、有公告机构审计记录、有上市后监督、有清晰责任主体（Manufacturer）。
一个真实案例：桂林南药（中国）的青蒿琥酯类产品，凭合规体系被国际组织采购，覆盖非洲、拉美、太平洋岛国。这就是 CE 的"放大器效应"——一次质量投入，撬动全球市场。 先拿 CE，再用临床数据扩展到 FDA / PMDA / NMPA，往往比单走中国 NMPA 更快、更经济、更全球化。
五、最容易踩的五个坑
我看过太多"合规做完了，商业上却失败"的案例，坑几乎固定：
- CE 做完卖不动 = 没做需求验证；
- 被代理"锁死" = 合同没退出机制；
- 医院进不去 = 没本地临床数据；
- 被 NB 拖死 = 分类/路线选错；
- 欧洲成本太高 = 没做本地化设计。
一句话总结：欧洲失败，从来不是因为"合规太难"，而是商业设计太晚。
六、三句话，送给正在犹豫的你
- "欧盟不是销售市场，是全球通行证市场。"
- "CE 不是终点，是融资和并购的起点。"
- "现在不来欧盟，也必须按欧盟标准做产品。"
最后这句尤其重要：今天是否进入欧盟，决定的不是你能不能出海，而是你未来还有没有资格参与全球竞争。 即使你 5 年内不进欧盟，按欧盟标准做产品，对企业的未来也至关重要。
今天的出海，不是因为那里更容易，而是因为只有穿过最难的海，才有星辰大海的梦想。
Why the EU Should Be Your First Stop Going Global
Around 2015, when Chinese pharma and device companies talked about going global, their eyes were fixed on the FDA. Today, if I had to give a board one sentence of advice, it would be: make the EU — not the US — your first stop.
It boils down to one line: the FDA is product access; the EU is company access. Let me unpack it.
1. Going global is no longer a choice — it is a must
When domestic demand shrinks and reimbursement cuts become a permanent structural reality, going global is the right remedy. The answer Japanese pharma and device companies gave in the 1990s is still there to study:
- Takeda went from "largest in Japan" to "global survival" by drawing its growth curve overseas early.
- Daiichi Sankyo was pushed by the market into becoming an ADC champion.
- Otsuka avoided the mainstream but globalised thoroughly.
Chinese companies moved early too: BeiGene out-licensed tislelizumab (PD-1) to Amgen; HutchMed handed savolitinib to AstraZeneca; RemeGen early-out-licensed its ADC platform to Seagen — that is "marriage-style going global". MicroPort acquired UK Penlon in 2022; Joincare spent RMB 1.587bn in 2025 acquiring Vietnam IMP Pharmaceuticals — that is "shell-style going global". Mindray, United Imaging, MicroPort and Fosun built their own teams or found local agents — that is "leverage-style going global".
Different paths, same direction: going out was only a matter of time.
2. One table: why the EU
Putting the world's major markets side by side, the conclusion is clear (industry estimates and public observation, 2025):
| Metric | US | EU | China | SE Asia |
|---|---|---|---|---|
| Market size | Largest (~40–50%) | Large (~20%) | Large (~7.5%) | Medium (~5%), fast growth |
| Payment ability & pricing | Highest | High | Medium | Lower-medium |
| Approval difficulty | Highest | Medium-high | Medium-high | Low-medium |
| Regulatory stability | High (but policy volatility) | Stable, tightening | Medium (reimbursement cuts dominate) | Low-medium (fragmented) |
| Global recognition | High | High | Medium | Low |
The global pharma and device market is estimated at USD 1.7–2.1 trillion (2025 estimate). The US is indeed the largest, but "largest" does not mean "easiest to enter".
3. America's hidden barriers are harder than the paper suggests
Many only see the FDA's strict review, not what stacks on top of it. In devices, the EU leans toward technical compliance + medical value, with relatively weak politics; US regulation is often not purely technical — device companies going to the US usually face extra gates:
- Data security / cybersecurity review
- National security review (CFIUS)
- Political and reputational risk
- Extra scrutiny of "Made in China"
On top of that: the EU is fragmented approval; the US is a single strong regulator. CE is reviewed by various Notified Bodies; each country has flexibility and room to negotiate, so smaller innovators and mature devices can "break through in batches". The FDA is the sole referee — extremely uniform, strict and traceable; one failure can damage global reputation.
On clinical data too: the EU is "good enough" — it accepts China local clinical data, retrospective studies and equivalence to comparable products; the FDA emphasises prospective, multi-centre, randomised controlled trials, with a very strict GCP system and highly auditable data. For most Chinese companies, the EU threshold is more realistic.
4. The right path: China → EU → LatAm/Middle East → back to the US
For most Chinese pharma and device companies, my suggested path is:
China → EU → LatAm / Middle East → back to the US.
The EU's value is to help you "build the foundation": polish the QMS, build global compliance experience, accumulate real-world usage data, and earn "international endorsement" (the CE mark). EMA approval means your product is recognised by one of the world's strictest systems scientifically. Once mature, knocking on the FDA's door raises success rates significantly.
More importantly: CE is not just the EU's ticket — it is a global passport. WHO PQ, UNICEF and the Global Fund all recognise CE — these organisations want a proven, auditable, sustainable quality endorsement system, and CE fits: based on ISO international consensus, with Notified Body audit records, post-market surveillance, and a clear responsible party (Manufacturer).
A real case: Guilin Pharmaceutical (China)'s artesunate products, through a compliant system, are procured by international organisations, covering Africa, LatAm and Pacific islands. That is CE's "amplifier effect" — one quality investment unlocks the global market. Get CE first, then expand to FDA / PMDA / NMPA with clinical data — often faster, cheaper and more global than going through China NMPA alone.
5. Five pitfalls
I have seen too many cases where "compliance was done but the business failed". The pitfalls are almost fixed:
- CE done but can't sell = no demand validation;
- Locked by an agent = no exit clause in contract;
- Can't get into hospitals = no local clinical data;
- Killed by the NB = wrong classification / route;
- Europe too costly = no localisation design.
One line: Europe fails not because "compliance is too hard", but because commercial design came too late.
6. Three lines for the hesitant
- "The EU is not a sales market; it is a global-passport market."
- "CE is not the finish line; it is the start of financing and M&A."
- "Even if you don't enter the EU now, you must build products to EU standards."
The last line matters most: whether you enter the EU today decides not whether you can go global, but whether you still qualify for global competition in the future. Even if you do not enter the EU within 5 years, building to EU standards is crucial for your future.
Today's going global is not because it is easier there, but because only by crossing the hardest sea can you reach the ocean of stars.